REKOMENDATsII EVROPEYSKOGO OBShchESTVA PO ARTERIAL'NOY GIPERTENZII VERSII 2009 GODA: ChTO IZMENILOS'?


Cite item

Full Text

Abstract

European Society of Hypertension version 2009 are discussed with changes in investigation and treatment strategy

About the authors

I E Chazova

V V Fomin

References

  1. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J. Hypertens. 2007; 25: 1105 - 1187
  2. Российское Медицинское Общество по Артериальной Гипертонии - Всероссийское Научное Общество Кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008
  3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J.A.M.A. 2002; 288: 2981 - 2997
  4. ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21: 1011 - 1053
  5. McCullough P.A., Li S., Jurkovitz CT. et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am. J. Kidney Dis. 2008; 51 (4 Suppl 2): S38-S45
  6. Шальнова С.А. Проблемы лечения артериальной гипертонии. Кардиоваскул. терапия и профилактика. 2003; 3: 17 - 21
  7. Faria C., Wenzel M., Lee K.W. et al. A narrative review of clinical inertia: focus on hypertension. J. Am. Soc. Hypertens. 2009; 3(4): 267-276
  8. Houlihan S.J., Simpson S.H., Cave A.J. et al. Hypertension treatment and control rates: chart review in an academic family medicine clinic. Can. Fam. Physician. 2009; 55(7): 735-741
  9. Karagiannis A., Hatzitolios A.I., Athyros V.G. et al. Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc. Med. J. 2009; 3: 26-34
  10. Lewis S.J., Robinson J.G., Fox K.M., Grandy S.; SHIELD Study Group. Underutilisation of cardiovascular medications among at-risk individuals. Int. J. Clin. Pract. 2010; 64(5): 604-610
  11. Belletti D.A., Zacker C., Wogen J. Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol. 2010; 9: 7
  12. Мычка В.Б., Чазова И.Е. Основные принципы лечения метаболического синдрома. М., 2009
  13. Parker E., Glasziou P. Use of evidence in hypertension guidelines: should we measure in both arms? Br. J. Gen. Pract. 2009; 59(560): e87-e92
  14. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-2158
  15. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358(15): 1547-1559
  16. Mann J.F., Schmieder R.E., McQueen M. et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372(9638): 547-553
  17. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S., Teo K., Anderson C. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644): 1174-1183
  18. Mochizuki S., Dahlof B., Taniguchi I. et al. for the JIKEI HEART Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439
  19. El Nahas M. Cardio-Kidney-Damage: a unifying concept. Kidney Int. 2010; 78(1): 14-18
  20. Karalliedde J., Viberti G. Microalbuminuria and cardiovascular risk. Am. J. Hypertens. 2004; 17(10): 986-993
  21. Beckett N.S., Peters R., Fletcehr A.E. et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898
  22. Yusuf S., Diener H.C., Sacco R.L. et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 2008; 359(12): 1225-1237
  23. Dahlof B., Sever P., Poulter N.R. et al., ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895 - 906
  24. The CAFÉ Investigators. Differential impact of blood-pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation. 2006 113(9): 1213 - 1225
  25. Jameson K., Weber M.A., Bakris G.L. et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417 - 2428
  26. Deeks E.D. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am. J. Cardiovasc. Drugs. 2009; 9(6): 411-418
  27. Bakris G.L., Sarafidis P.A., Weir M.R. et al.; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375(9721): 1173-1181
  28. Alleman Y., Fraile B., Lambert M. et al. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: the Exforge in Failure after Single Therapy (Ex-FAST) Study. J. Clin Hypertens. (Greenwich). 2008; 10(3): 185 - 194
  29. Destro M., Luckow A., Samson M. et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized double-blind multicenter study: the EX-EFFeCTS Study. J. Am. Soc. Hypertens. 2008; 2(4): 294-302
  30. Чазова И.Е., Карпов Ю.А., Вигдорчик А.В. от лица исследовательской группы. Эффективность и безопасность комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: первые результаты российского наблюдательного исследования ЭКСТРА. Системные гипертензии. 2010; 2: 18-26
  31. Boutouyrie P., Achouba A., Trunet P., Laurent S.; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010; 55(6): 1314-1322
  32. Zoungas S., de Galan B.E., Ninomiya T. et al. on behalf of the ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes. New results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074
  33. Yusuf S., Pais P., Afzal R. et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS) : a phase II, double-blind, randomized trial. Lancet 2009; 373: 1341-1351

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies